Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Type of study
Language
Affiliation country
Publication year range
1.
Adv Healthc Mater ; 12(9): e2202676, 2023 04.
Article in English | MEDLINE | ID: mdl-36535275

ABSTRACT

Alkaline phosphatase (ALP) is a tumor marker for early diagnosis and treatment. Tumor targeting can recognize and fight tumor cells more accurately from healthy cells. Glycyrrhetinic acid (GA) is a targeting ligand of liver tumors. Photoacoustic imaging (PAI) and photothermal therapy (PTT) are promising techniques for tumor diagnosis and treatment. The outstanding characteristics of Hemicyanine (HCy) dye make it suitable for tumor diagnosis and treatment. However, using HCy nanoparticle (HCy NP) for liver tumor-targeting PAI and PTT has not been reported. Herein, Probe-1 is developed to enhance PAI and PTT of liver tumors due to GA targeting and intracellular ALP-instructed self-assembly of HCy NP. Compared to Probe-2 without self-assembly ability, Probe-1 displays a 4.6-fold higher PAI signal or 1.7-fold lower half inhibitory concentrations in HepG2 cells. Moreover, Probe-1 shows extended retention time (10 vs 6 h) and 2.1-fold higher PAI signal than Probe-2 in HepG2 tumors. The HepG2 tumors in Group Probe-1 obviously increase 18 °C (Tmax : 55 °C) with a 3.3-fold decreased volume while that in Group Probe-2 mildly increase 9.8 °C (Tmax : 46.8 °C) with a 4.3-fold increased volume. It is envisioned that this smart self-assembly strategy can be easily adjusted for PAI and PTT of more tumors.


Subject(s)
Liver Neoplasms , Nanoparticles , Neoplasms , Photoacoustic Techniques , Humans , Photothermal Therapy , Photoacoustic Techniques/methods , Neoplasms/diagnostic imaging , Neoplasms/therapy , Nanoparticles/therapeutic use , Phototherapy/methods , Liver Neoplasms/therapy
2.
Chem Commun (Camb) ; 58(96): 13329-13332, 2022 Dec 01.
Article in English | MEDLINE | ID: mdl-36373630

ABSTRACT

A tumor-targeting therapy strategy is urgently needed to increase the accumulation of drugs in tumors and reduce the side effects in normal tissues. Herein, we developed an esterase-activatable curcumin prodrug Cur-RGD for tumor-targeting therapy. Armed with the tumor-targeting RGD peptide and in situ esterase-triggered drug release, this prodrug Cur-RGD can efficiently improve the therapeutic effect of curcumin in tumors.


Subject(s)
Antineoplastic Agents , Curcumin , Nanoparticles , Neoplasms , Prodrugs , Humans , Curcumin/pharmacology , Prodrugs/pharmacology , Prodrugs/therapeutic use , Esterases , Oligopeptides , Neoplasms/drug therapy , Drug Carriers/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cell Line, Tumor
SELECTION OF CITATIONS
SEARCH DETAIL